Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Vericiguat in Subjects With Renal Impairment
NCT04722484Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (5 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve of Vericiguat up to 96 hours, Maximum Plasma Concentration of Vericiguat up to 96 hours and 2 more. Started Jun 2014; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04722484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722484.